Entera is a clinical stage company focused on developing oral peptide or protein replacement therapies for significant unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The Company leverages on a disruptive and proprietary technology platform (N-Tab™) and its pipeline includes five differentiated, first-in-class oral peptide programs, expected to enter the clinic (Phase 1 to Phase 3) by 2025.
The Company’s most advanced product candidate, EB613 (oral PTH (1-34)), is being developed as the first oral, osteoanabolic (bone building) once-daily tablet treatment for post-menopausal women with low BMD and high-risk osteoporosis. A placebo controlled, dose ranging Phase 2 study of EB613 tablets (n= 161) met primary (PD/bone turnover biomarker) and secondary endpoints (BMD). Entera is preparing to initiate a Phase 3 registrational study for EB613 pursuant to the FDA’s qualification of a quantitative BMD endpoint which is expected to occur by January 2025.
The EB612 program is being developed as the first oral PTH(1-34) tablet peptide replacement therapy for hypoparathyroidism. Entera is also developing the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity; and first oral GLP-2 peptide tablet as an injection-free alternative for patients suffering from rare malabsorption conditions such as short bowel syndrome in collaboration with OPKO Health.
For more information on Entera Bio, visit www.enterabio.com or follow us on LinkedIn, Twitter, Facebook, Instagram.
Company Details
- Employees
- 20
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- enterabio.com
Entera Bio Ltd. Questions
Entera Bio Ltd.'s website is enterabio.com
Entera Bio Ltd.'s LinkedIn profile is https://il.linkedin.com/company/entera-bio
Entera Bio Ltd. has
20 employees.
View email and phone details for 20
employees at Entera Bio Ltd..
Entera Bio Ltd.'s industry is
Biotechnology Research
Entera Bio Ltd.'s top competitors are
Rezolute, Inc.,
Exicure,
Bright Minds Biosciences,
Kodiak Sciences,
Cardiff Oncology,
Pulmatrix Inc.,
Asp Isotopes,
Monopar Therapeutics Inc.,
Benitec Biopharma Inc.,
Jasper Therapeutics.
Entera Bio Ltd.'s categories are Biotechnology Research
Entera Bio Ltd.'s founding year is 2010
